Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease

Archives of Disease in Childhood

Volumn 98, Issue 4, 2013, Pages 248-251

  Pollard, Andrew J ^a,b   Green, Christopher ^a   Sadarangani, Manish ^a   Snape, Matthew D ^a  

^a NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE; DIPHTHERIA TOXOID; SEROGROUP C MENINGOCOCCAL CONJUGATE VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL COLONIZATION; DISEASE CONTROL; DISEASE TRANSMISSION; EPIDEMIC; HAEMOPHILUS INFLUENZAE; INCIDENCE; MEMORY CELL; MENINGOCOCCOSIS; NASOPHARYNX; NEISSERIA MENINGITIDIS; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; UNITED KINGDOM; EARLY DIAGNOSIS; HERD IMMUNITY; HUMAN; IMMUNOLOGICAL MEMORY; RISK FACTOR; SEROGROUP C MENINGOCOCCAL IMMUNIZATION PROGRAM; SERUM BACTERICIDAL ANTIBODY ASSAY; SMOKING;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; GREAT BRITAIN; HUMANS; IMMUNIZATION, SECONDARY; INFANT; MASS VACCINATION; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP C; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84876176610     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2012-303103     Document Type: Article

References (30)

1. Department of Health. Joint Committee on Vaccination and Immunisation, Minute of the meeting on Wednesday 3 October 2012. London, 2012. https://www.wp.dh.gov.uk/transparency/files/2012/07/JCVI-minutes-13-June-2012- draft.pdf (accessed 1 March 2013).
2. MacLennan J, Kafatos G, Neal K, et al. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis 2006;12:950-7.
3. Gray SJ, Trotter CL, Ramsay ME, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006;55:887-96.
4. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001;20 (Suppl 1):S58-67.
5. Trotter CL, Ramsay ME, Kaczmarski EB. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun Dis Public Health 2002;5:220-5.
6. Health Protection Agency. Table 1: Invasive meningococcal infections laboratory reports, England and Wales by capsular group & epidemiological year, 1998/99-2011/12. 2012.
7. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004;364:365-7.
8. Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010;10: 853-61.
9. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009;9:213-20.
10. Matsunami T, Kolmer JA. The relation of the meningococcidal activity of the blood to resistance to virulent meningococci. J Immunol 1918;3:201-12.
11. Heist GD, Solis-Cohen S, Solis-Cohen M. A study of the virulence of meningococci for man and of human susceptibility to meningococcic infection. J Immunol 1922;7:1-33.
12. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969;129: 1307-26.
13. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 2005;23:2222-7.
14. Kelly DF, Snape MD, Clutterbuck EA, et al. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood 2006;108:2642-7.
15. Kelly DF, Snape MD, Perrett KP, et al. Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine. Immunology 2009;127:134-43.
16. Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 2005;5:21-30.
17. Khatami A, Snape MD, John T, et al. Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial. Pediatr Infect Dis J 2011;30: 197-202.
18. Ishola DA Jr, Borrow R, Findlow H, et al. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction. Clin Vaccine Immunol 2012;19:1126-30.
19. Perrett KP, Winter AP, Kibwana E, et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis 2010;50:1601-10.
20. Snape MD, Kelly DF, Salt P, et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 2006;43:1387-94.
21. Southern J, Borrow R, Andrews N, et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol 2009;16: 194-9.
22. Southern J, Crowley-Luke A, Borrow R, et al. Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine 2006;24:215-19.
23. Findlow H, Borrow R, Andrews N, et al. Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United Kingdom. Pediatr Infect Dis J 2012;31:616-22.
24. De Wals P, Deceuninck G, Lefebvre B, et al. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. Pediatr Infect Dis J 2011;30: 566-9.
25. Khatami A, Snape MD, Davis E, et al. Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. Vaccine 2012;30:2831-8.
26. Borrow R, Goldblatt D, Andrews N, et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis 2002;186:1353-7.
27. Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008;299:173-84.
28. Khatami A, Snape MD, Wysocki J, et al. Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study. Pediatr Infect Dis J 2012;31:1069-73.
29. Snape MD, Kelly DF, Lewis S, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 2008;336:1487-91.
30. Khatami A, Peters A, Robinson H, et al. Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood. Clin Vaccine Immunol 2011;18: 2038-42.